Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. BRS Analytical Services, LLC
WARNING LETTER
•BRS Analytical Services, LLC•March 26, 2025

BRS Analytical Services, LLC – FDA Warning Letter, Mar 26, 2025

Record Details

The FDA issued a Warning Letter to BRS Analytical Services, LLC following an inspection from March 10 to 26, 2025, at their St. Louis drug manufacturing and testing facility. The letter cites significant violations of Current Good Manufacturing Practice (CGMP) regulations, specifically 21 CFR parts 210 and 211, which led to their drug products being deemed adulterated under section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act.Key issues include a fundamentally unsuitable ISO 5 cleanroom design, featuring physical gaps and inadequate pressure control, which posed an unacceptable risk to the sterility of their sterile over-the-counter drugs. Environmental monitoring was found deficient, lacking routine viable air monitoring and proper particle monitor placement, and data was not routinely reviewed before batch release. Facility maintenance issues, such as discoloration and unclean surfaces, were also observed.Furthermore, the company failed to establish and follow appropriate procedures to prevent microbiological contamination. Inspectors noted poor aseptic practices, including operators blocking unidirectional airflow and using nonsterile materials. The media fill program was inadequate, with insufficient unit incubation and shortened simulation durations compared to commercial operations. Sterilization assurance was lacking, as the validation process for direct product contact parts was insufficient, and sterilizing filters were not routinely integrity tested. An inadequate smoke study also failed to demonstrate proper unidirectional airflow. BRS Analytical Services, LLC must address these critical deficiencies to ensure the quality and sterility of their drug products.

Company
BRS Analytical Services, LLC
Inspection date
March 26, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · fc3bbd24-8308-47f8-8168-be4655ba585e

Violation Codes9
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 211FD&C Act 501(a)(2)(B)21 CFR 211.42(c)(10)21 CFR 211.6321 CFR 211.113(b)21 CFR 211.2221 CFR 211.34

Full citation text and observation details available on the Dashboard.

Other documents for BRS Analytical Services, LLC
  • 483 - 2025-03-26March 26, 2025

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore BRS Analytical Services, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.